Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial - Annals of Oncology
Merck's targeted lung cancer drug tepotinib wins early access in UK -
Schematic representation of MET signaling blockade by capmatinib.... | Download Scientific Diagram
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
FDA approved ALK inhibitors with substantial impact in the field of... | Download Scientific Diagram
Novartis Reports Results of Capmatinib in P-II GEOMETRY mono-1 Study for Non-Small Cell
Contemporary Developments in MET-Selective Kinase Inhibitors in Advanced Non–Small-Cell Lung Cancer
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Novartis' MET inhibitor Tabrecta wins permit for lung cancer in Korea < Pharma < 기사본문 - KBR
Capmatinib (INC280) | Selective MET Inhibitor | MedChemExpress
MET-dependent solid tumours — molecular diagnosis and targeted therapy | Nature Reviews Clinical Oncology
Has PD-1 MET Its Match in Hepatocellular Carcinoma? - Gastroenterology
Biomedicines | Free Full-Text | Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment | HTML
Novartis bags FDA priority review in tight lung cancer race against Merck KGaA | Fierce Pharma
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study - The Lancet Oncology
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
Novartis cancer therapy MET inhibitor capmatinib granted USFDA priority review
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor - Journal of Thoracic Oncology
Tabrecta (capmatinib) for the Treatment of Non-Small Cell Lung Cancer
FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14 | Pharmafile
Real-world insights into patients with advanced NSCLC and MET alterations - Lung Cancer
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Novartis' Powerful MET Inhibitor Tabrecta Has A Strong Therapeutic Effect On METex14 Mutant Non-small Cell Lung Cancer (NSCLC)! - Industry news - News - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd
JCM | Free Full-Text | The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer | HTML
